The Down Under medical landscape is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in scientific trials for treating obesity. This therapy https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/